FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
MLND Financial Statements
Year
2020
2019
2018
2017
CF from Operating Activities
-30.43M
-41.22M
-23.65M
-45.55M
Net Income
-36.41M
-44.57M
-27.19M
-50.98M
Depreciation & Amortization
1.1M
1.05M
32k
1.65M
Deferred Income Taxes
0
0
0
0
Stock Based Compensation
4.24M
4.32M
1.43M
6.89M
Change in Working Capital
296k
-2.05M
1.04M
-4.75M
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
25k
-469k
320k
68k
Other Working Capital
271k
-1.58M
716k
-4.82M
Other Non-Cash Items
327k
30k
1.05M
1.63M
CF from Investing Activities
-26k
3.99M
1.93M
17.32M
Investments in Property, Plant & Equipment
-26k
-397k
-36k
-158k
Net Acquisitions
0
0
-524k
-1.1M
Investment Purchases
0
0
0
-68.86M
Sales/Maturities of Investments
0
4.38M
2.49M
87.79M
Other Investing Activites
0
0
0
-350k
CF from Financing Activities
5.39M
26.94M
77.74M
0
Debt Repayment
-145k
-202k
-169k
0
Common Stock Issued
5.45M
26.67M
38.76M
0
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
5.39M
26.94M
77.74M
0
Free Cash Flow
-30.46M
-41.62M
-23.68M
-45.71M
Operating Cash Flow
-30.43M
-41.22M
-23.65M
-45.55M
Capital Expenditures
-26k
-397k
-36k
-158k
Cash at Beginning of Period
63.51M
73.77M
17.62M
43.93M
Cash at End of Period
38.66M
63.51M
73.77M
15.7M
Net Change In Cash
-24.85M
-10.26M
56.15M
-28.23M
All figures are in USD.
